Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition.

MLA

Salo, Tuula, et al. “Chemically Modified Tetracyclines (CMT-3 and CMT-8) Enable Control of the Pathologic Remodellation of Human Aortic Valve Stenosis via MMP-9 and VEGF Inhibition.” International Journal of Cardiology, vol. 111, no. 3, Aug. 2006, pp. 358–64. EBSCOhost, https://doi.org/10.1016/j.ijcard.2005.07.042.

APA

Salo, T., Soini, Y., Oiva, J., Kariylitalo, Nissinen, A., Biancari, F., Juvonen, T., & Satta, J. (2006). Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition. International Journal of Cardiology, 111(3), 358–364. https://doi.org/10.1016/j.ijcard.2005.07.042

Chicago

Salo, Tuula, Ylermi Soini, Jani Oiva, Kariylitalo, Antti Nissinen, Fausto Biancari, Tatu Juvonen, and Jari Satta. 2006. “Chemically Modified Tetracyclines (CMT-3 and CMT-8) Enable Control of the Pathologic Remodellation of Human Aortic Valve Stenosis via MMP-9 and VEGF Inhibition.” International Journal of Cardiology 111 (3): 358–64. doi:10.1016/j.ijcard.2005.07.042.